RxDoctor Payments DataLook up a doctor →

Traci Purath, MD

Neurology · Burlington, WINPI 1891716700

Payments from drug & device makers

$524,067in general payments, 2019–2025

Across 745 payments — averaging $703.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$241K
  • Biohaven Pharmaceutical Holding Company Ltd.$93K
  • Pfizer$61K
  • Amgen$49K
  • Axsome Therapeutics, Inc.$23K
  • Impel Pharmaceuticals Inc.$22K
  • plus $35K from 7 others

What the payments were for

  • Consulting fees$18,6804%
  • Speaking & faculty fees$453,28486%
  • Grants$880%
  • Travel & lodging$40,2378%
  • Food & beverage$11,7782%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$524,067 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Wisconsin.

See all neurology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$114,883
Medicare patients
118
Services billed
11,362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina64$89,183
Nurtec OdtRimegepant Sulfate47$81,760
QuliptaAtogepant36$46,496
Aimovig AutoinjectorErenumab-Aooe48$46,422
Emgality PenGalcanezumab-Gnlm51$40,393
UbrelvyUbrogepant18$21,034
Sumatriptan Succinate55$5,380
Gabapentin164$4,147
RizatriptanRizatriptan Benzoate72$2,172
Tizanidine Hcl103$1,791
Eletriptan HbrEletriptan Hydrobromide31$1,641
Butorphanol Tartrate11$1,081
Primidone11$853
Naratriptan Hcl16$816
Zonisamide29$811

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Qulipta, Ubrelvy$240,793$156,714118 claims
PfizerNurtec Odt$61,073$81,76047 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 neurology providers in Wisconsin.

Other neurology in Burlington

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →